242 related articles for article (PubMed ID: 20720566)
1. Association between the germline MC1R variants and somatic BRAF/NRAS mutations in melanoma tumors.
Scherer D; Rachakonda PS; Angelini S; Mehnert F; Sucker A; Egberts F; Hauschild A; Hemminki K; Schadendorf D; Kumar R
J Invest Dermatol; 2010 Dec; 130(12):2844-8. PubMed ID: 20720566
[No Abstract] [Full Text] [Related]
2. Germline MC1R variants and BRAF mutant melanoma.
Hacker E; Hayward NK
J Invest Dermatol; 2008 Oct; 128(10):2354-6. PubMed ID: 18787543
[TBL] [Abstract][Full Text] [Related]
3. MC1R germline variants confer risk for BRAF-mutant melanoma.
Landi MT; Bauer J; Pfeiffer RM; Elder DE; Hulley B; Minghetti P; Calista D; Kanetsky PA; Pinkel D; Bastian BC
Science; 2006 Jul; 313(5786):521-2. PubMed ID: 16809487
[TBL] [Abstract][Full Text] [Related]
4. Germline MC1R variants and frequency of somatic BRAF, NRAS, and TERT mutations in melanoma: Literature review and meta-analysis.
Zanna I; Caini S; Raimondi S; Saieva C; Masala G; Massi D; Cocorocchio E; Queirolo P; Stanganelli I; Gandini S
Mol Carcinog; 2021 Mar; 60(3):167-171. PubMed ID: 33444485
[TBL] [Abstract][Full Text] [Related]
5. BRAF, NRAS and MC1R status in a prospective series of primary cutaneous melanoma.
García-Casado Z; Traves V; Bañuls J; Niveiro M; Gimeno-Carpio E; Jimenez-Sanchez AI; Moragón M; Onrubia JA; Oliver V; Kumar R; Nagore E
Br J Dermatol; 2015 Apr; 172(4):1128-31. PubMed ID: 25385688
[No Abstract] [Full Text] [Related]
6. Relationship between germline MC1R variants and BRAF-mutant melanoma in a North Carolina population-based study.
Thomas NE; Kanetsky PA; Edmiston SN; Alexander A; Begg CB; Groben PA; Hao H; Busam K; Ollila DW; Berwick M; Conway K
J Invest Dermatol; 2010 May; 130(5):1463-5. PubMed ID: 20043015
[No Abstract] [Full Text] [Related]
7. NRAS and BRAF mutations in cutaneous melanoma and the association with MC1R genotype: findings from Spanish and Austrian populations.
Hacker E; Nagore E; Cerroni L; Woods SL; Hayward NK; Chapman B; Montgomery GW; Soyer HP; Whiteman DC
J Invest Dermatol; 2013 Apr; 133(4):1027-33. PubMed ID: 23096702
[TBL] [Abstract][Full Text] [Related]
8. Molecular characterization of human cutaneous melanoma-derived cell lines.
Ogbah Z; Puig-Butille JA; Simonetta F; Badenas C; Cervera R; Milá J; Benitez D; Malvehy J; Vilella R; Puig S
Anticancer Res; 2012 Apr; 32(4):1245-51. PubMed ID: 22493355
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneity of BRAF, NRAS, and TERT Promoter Mutational Status in Multiple Melanomas and Association with MC1R Genotype: Findings from Molecular and Immunohistochemical Analysis.
Pellegrini C; Di Nardo L; Cipolloni G; Martorelli C; De Padova M; Antonini A; Maturo MG; Del Regno L; Strafella S; Micantonio T; Leocata P; Peris K; Fargnoli MC
J Mol Diagn; 2018 Jan; 20(1):110-122. PubMed ID: 29061376
[TBL] [Abstract][Full Text] [Related]
10. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.
Goel VK; Lazar AJ; Warneke CL; Redston MS; Haluska FG
J Invest Dermatol; 2006 Jan; 126(1):154-60. PubMed ID: 16417231
[TBL] [Abstract][Full Text] [Related]
11. Lack of somatic alterations of MC1R in primary melanoma.
Kim RD; Curtin JA; Bastian BC
Pigment Cell Melanoma Res; 2008 Oct; 21(5):579-82. PubMed ID: 18761657
[TBL] [Abstract][Full Text] [Related]
12. The association between MC1R genotype and BRAF mutation status in cutaneous melanoma: findings from an Australian population.
Hacker E; Hayward NK; Dumenil T; James MR; Whiteman DC
J Invest Dermatol; 2010 Jan; 130(1):241-8. PubMed ID: 19571821
[TBL] [Abstract][Full Text] [Related]
13. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.
Edlundh-Rose E; Egyházi S; Omholt K; Månsson-Brahme E; Platz A; Hansson J; Lundeberg J
Melanoma Res; 2006 Dec; 16(6):471-8. PubMed ID: 17119447
[TBL] [Abstract][Full Text] [Related]
14. Dermoscopic criteria associated with BRAF and NRAS mutation status in primary cutaneous melanoma.
Pozzobon FC; Puig-Butillé JA; González-Alvarez T; Carrera C; Aguilera P; Alos L; Badenas C; Grichnik JM; Malvehy J; Puig S
Br J Dermatol; 2014 Oct; 171(4):754-9. PubMed ID: 24749938
[TBL] [Abstract][Full Text] [Related]
15. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis.
Lee JH; Choi JW; Kim YS
Br J Dermatol; 2011 Apr; 164(4):776-84. PubMed ID: 21166657
[TBL] [Abstract][Full Text] [Related]
16. MC1R variants increase risk of melanomas harboring BRAF mutations.
Fargnoli MC; Pike K; Pfeiffer RM; Tsang S; Rozenblum E; Munroe DJ; Golubeva Y; Calista D; Seidenari S; Massi D; Carli P; Bauer J; Elder DE; Bastian BC; Peris K; Landi MT
J Invest Dermatol; 2008 Oct; 128(10):2485-90. PubMed ID: 18368129
[TBL] [Abstract][Full Text] [Related]
17. BRAF and MC1R in melanoma: different in head and neck tumors?
Fink EC; Fisher DE
J Invest Dermatol; 2013 Apr; 133(4):878-80. PubMed ID: 23486431
[TBL] [Abstract][Full Text] [Related]
18. BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival.
Akslen LA; Angelini S; Straume O; Bachmann IM; Molven A; Hemminki K; Kumar R
J Invest Dermatol; 2005 Aug; 125(2):312-7. PubMed ID: 16098042
[TBL] [Abstract][Full Text] [Related]
19. Germline variation of the melanocortin-1 receptor does not explain shared risk for melanoma and thyroid cancer.
Bauer J; Weng J; Kebebew E; Soares P; Trovisco V; Bastian BC
Exp Dermatol; 2009 Jun; 18(6):548-52. PubMed ID: 19493000
[TBL] [Abstract][Full Text] [Related]
20. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M
Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
